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Background: Elizabethkingia meningoseptica, formerly known as Chryseobacterium menin-
gosepticum, is a non-motile, non-fastidious, catalase and oxidase-positive, aerobic, glucose-
non-fermentative, Gram-negative bacillus that was first defined by Elizabeth O. King in 1959. 
It has emerged as an opportunistic pathogen that has infected patients in extreme age groups 
and immunocompromised individuals, especially in intensive care settings. There has been an 
increased interest in this pathogen due to its increasing occurrence around the world, ubiqui-
tous nature, and inherent capacity for antimicrobial resistance. 
Methods: We describe an observational study at a tertiary care center in Karachi, Pakistan, 
based on patients admitted between January 2013 and December 2018, with E. meningosep-
tica infections. All patients were confirmed to have a positive clinical culture specimen for E. 
meningoseptica along with symptoms and signs consistent with infection. Data were collect-
ed on a structured proforma from the Hospital Information Management Systems. 
Results: Sixteen patients with E. meningoseptica that met the criteria for infection were iden-
tified, 13 of whom required admission. Eight patients had bacteremia in addition to confirmed 
E. meningoseptica infection. Two of the isolates were multi-drug resistant and only sensitive to 
minocycline. Nine out of 13 patients that were admitted required intubation and mechanical 
ventilation. The median length of hospital stay was 13 days, and five out of the 13 patients died 
during the hospital stay. 
Conclusion: This is the largest case series to date reporting E. meningoseptica infections and 
highlights the importance of this organism as an emerging nosocomial pathogen.
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INTRODUCTION
Elizabethkingia meningoseptica, formerly known as Chryseobacterium meningosepticum, is a 
non-motile, non-fastidious, catalase and oxidase-positive, aerobic, glucose-non-fermentative, 
Gram-negative bacillus that was first defined by Elizabeth O. King in 1959 [1]. The Elizabeth-
kingia genus has been noted due to the genetic makeup that facilitates a large degree of genetic 
variability and subsequent antimicrobial resistance. This, combined with lack of literature re-
ports on the wide distribution in nature and of adequate treatment regimens have led to high 
mortality rates in hospital-settings, particularly in intensive care units (ICUs), since 2004 [2]. 
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 E. meningoseptica is isolated most frequently from soil, salt-
water, and freshwater and from dry and moist clinical envi-
ronmental and equipment surfaces, intravenous lipid solu-
tions, and municipal water supplies, including those adequate-
ly chlorinated [3]. Although nearly ubiquitous in nature, it is 
an uncommon human pathogen. E. meningoseptica predom-
inately causes outbreaks of meningitis in immunocompro-
mised patients, particularly in premature newborns and in-
fants in neonatal ICUs of developing countries [4]. The bacte-
rium is a rare cause of nosocomial pneumonia, endocarditis, 
and meningitis in immunocompromised adults. More recent-
ly, in the past few years, it has been found to cause soft tissue 
infection and sepsis in immunocompetent adults [5]. 
 In a study from Wisconsin, 48 cases of Elizabethkingia in-
fection were reported during an outbreak, which resulted in 
17 deaths in a 5-month period beginning in November 2015 
[6]. Another case series showed that the yearly incidence of E. 
meningoseptica bacteremia increased substantially from 2002 
to 2006 (from 6.8–13.1 to 26.6–39.9 per 100,000 admissions; 
P = 0.006) [7]. 
 Moreover, Elizabethkingia, similar to its genetic relative chry-
seobacterium species, is inherently extensively drug resistant. 
It is resistant to a broad spectrum of antibiotic classes, includ-
ing macrolides, tetracyclines, linezolid, polymyxin group, chlor-
amphenicol, aminoglycosides, and beta-lactam drugs [8]. Van-
comycin, rifampicin, new fluoroquinolones, piperacillin-tazo-
bactam, and minocycline are the current preferred empirical 
choices for treating E. meningoseptica infections. 
 E. meningoseptica is an important emerging opportunistic 
bacterium that primarily occurs in nosocomial settings. It is 
unclear which treatment regimen is most effective and what 
factors are associated with adverse outcomes. The aim of this 
study is to describe the clinical features and outcomes of E. 
meningoseptica infections in a tertiary care center in Karachi, 
Pakistan. 
MATERIALS AND METHODS
The study received an exemption from ethical approval from 
the Aga Khan University Ethics Review Committee (ERC #2019-
1786-4439) and requirement of informed consent was waived 
due to retrospective nature of study. Data was anonymized 
and no personal identifiers were collected.
 This was an observational study of patients admitted be-
tween January 2013 and December 2018, with E. meningosep-
tica infections. All patients were confirmed to have a positive 
clinical culture specimen for E. meningoseptica along with 
KEY MESSAGES 
■  Elizabethkingia meningoseptica is an opportunistic 
pathogen infecting people in the extremes of age and 
the immunocompromised, especially in intensive care 
settings. 
■  We are describing the largest case series to date report-
ing E. meningoseptica infections. 
■  Our study found that Chryseobacterium meningosepti-
cum is an emerging nosocomial pathogen causing mor-
tality in patients requiring intensive care and outcomes 
are better if isolates are susceptible to quinolones.
signs and symptoms consistent with infection. All patients 
presumed to be colonized but not infected were excluded. 
Data were collected on a structured proforma from the Hospi-
tal Information Management Systems. Identification and sus-
ceptibility of E. meningoseptica isolated from cultures were 
performed by automated systems in accordance with Clinical 
Laboratory Standards Institute recommendations. Identifica-
tion of E. meningoseptica was determined by a Vitek 2 system 
(bioMerieux, Marcy-l’Étoile, France).
Definitions
Infection was defined based on clinical presentation along 
with patient-related factors and microbiological diagnosis. The 
Center for disease control/National Healthcare Safety Network 
definitions [9] for specific types of infections were used. A mul-
tidisciplinary team of doctors including infectious disease 
consultants, pulmonologists, and intensivists was involved in 
case identification and management. Patients were consid-
ered to be colonized if they had positive culture results for the 
organism but no signs and symptoms to suggest active infec-
tion based on the primary physician evaluation and contin-
ued status of good health without treatment. Patients were 
considered to have co-infection if a clinically significant true 
pathogen was identified simultaneously from a culture speci-
men and the patient improved after corresponding treatment. 
Patients were considered to have co-colonization if the patho-
gen isolated was a known contaminant or did not produce 
signs and symptoms consistent with infection. Polymicrobial 
infection was defined as the presence of another bacteria or 
fungi in the same culture specimen. Multi-drug resistance was 
defined as acquired non-susceptibility to at least one agent in 
three or more antimicrobial categories [10]. Death was con-
firmed as all-cause mortality during hospitalization. 
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Statistical Analysis
Data were analyzed using IBM SPSS ver. 19 (IBM Corp., Ar-
monk, NY, USA). Descriptive analysis was performed for de-
mographic features with median and interquartile range val-
ues reported for quantitative variables such as age and length 
of hospital stay, and frequency (percentage) were reported for 
qualitative variables such as sex, comorbid conditions, mor-
tality, and complications. A P-value ≤ 0.05 was considered sta-
tistically significant. Data were kept confidential, and no per-
sonal identifiers were used. 
RESULTS
Sixteen patients with E. meningoseptica infections were iden-
tified between 2013 and 2018, 13 of whom required hospital 
admission, constituting an infection rate of 2.9 per 100,000 
admissions. The median age was 29 years for six males and 
seven females, with ages ranging from 3 days to 83 years. The 
most common comorbid conditions were diabetes (5/13) and 
hypertension (5/13). The average Charlson’s comorbidity in-
dex was 3.3. Three patients had underlying malignancy, and 
five patients had a history of repeated hospitalization. Eleven 
patients were admitted to the ICU. Eight of 13 patients had 
bacteremia with E. meningosepticum, and the most common 
source of bacteremia was central line-associated bloodstream 
infection in six patients. Among other sites of infection, one 
had urinary tract infection, two had meningitis, two had pneu-
monia, and one had infective endocarditis. Nine patients had 
mono-microbial growth, whereas four had polymicrobial growth 
in culture. Of 13 patients, eight required a Foley catheter and 
nine required a central venous catheter, endotracheal intuba-
tion, and mechanical ventilation. The clinical characteristics 
Table 1. Summary of patients with Elizabethkingia meningoseptica infections
No. Age/sex Associated disease Site of infection Type of strain Treatment Outcome
  1 Term baby at the 2nd day of 
life
None Meningitis Drug sensitive Ciprofloxacin Recovered
  2 Preterm 33-week-baby girl 







Drug sensitive Minocycline Recovered
  3 5 day/F Subglottic stenosis Bloodstream infection 
(source unclear)
Drug sensitive Levofloxacin Recovered
  4 19 yr/M SLE, CKD Central line-associated 
bloodstream infection
Drug sensitive Cotrimoxazole Recovered
  5 22 yr/M Status post-RTA with anoxic 







  6 25 yr/F Pregnancy induced hyper-
tension, post-partum hem-
orrhage
Urinary tract infection Drug sensitive Cefixime Recovered
  7 29 yr/M Dengue hemorrhagic fever Central line-associated 
Bloodstream infection
Drug sensitive Meropenem Recovered
  8 41 yr/F DM, HTN, APLA syndrome, 
left MCA stroke









Drug sensitive Levofloxacin Death
10 58 yr/M DM, HTN, IHD Hospital-acquired pneumo-
nia
Drug resistant Cotrimoxazole Death




Drug sensitive Minocycline Death
12 76 yr/F DM, HTN, IHD, CKD Meningitis Drug sensitive Levofloxacin+  
cotrimoxazole
Recovered
13 86 yr/M DM, HTN, IHD Central line-associated 
bloodstream infection
Drug sensitive Levofloxacin Death
NICU: neonatal intensive care unit; SLE: systemic lupus erythematosus; CKD: chronic kidney disease; RTA: road traffic accident; DM: diabetes mellitus; 
HTN: hypertension; APLA: anti-phospholipid antibody; MCA: middle cerebral artery; IHD: ischemic heart disease; CLD: chronic liver disease. 
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of all 13 patients are summarized in Table 1. E. meningosepti-
cum was sensitive to quinolones in five of 13 isolates. Two of 
the E. meningosepticum isolates were multi- drug resistant 
with sensitivity only to minocycline, which was the drug used 
for definitive treatment. The susceptibility pattern of all iso-
lates is summarized in Figure 1. Five of 13 patients were treat-
ed with a quinolone, four with cotrimoxazole, and four with 
minocycline. However, culture appropriate antibiotics were 
not initiated in two patients. The most common co-infection 
was with multi-drug resistant Acinetobacter (n = 2) or Pseudo-
monas aeruginosa (n = 2). Five of 13 patients died, two cases 
were referred for palliative care in view of advanced underly-
ing malignancy, and the median length of hospital stay was 13 
days. All five patients who died had a history of repeat hospi-
talization and significant comorbidities. All five of these pa-
tients were mechanically ventilated and underwent invasive 
catheterization. E. meningoseptica was isolated from the blood 
of three patients and from tracheal aspirate in one patient who 
had undergone esophagectomy, thoracotomy, and tracheos-
tomy. Death could be attributed to E. meningoseptica infec-
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Table 2. Summary of studies reporting Elizabethkingia infections and outcomes
Study Sample size Clinical diagnosis Risk factor Treatment Outcome
Khan et al. [11] (2015) 4 Empyema, peritonitis, en-
docarditis, intra-abdomi-
nal sepsis





3 Survived;  
1 died
Arbune et al. [12] (2018) 1 Meningitis Preterm baby Piperacillin, tazobactam, and 
Rifampin
Survived
Celik et al. [13] (2019) 3 Ventilator-associated 
pneumonia
Preterm infants One baby treated with cefo-
perazone-sulbactam and 2 
babies treated with cipro-
floxacin
All survived




Pediatric patients requiring 
intensive care
Treatment details not avail-
able
All survived 
Sahu et al. [15] (2019) 1 Ventilator-associated 
pneumonia





Raghavan et al. [16] 
(2017)
1 Urinary tract infection Congestive heart failure Minocycline Survived
Dziuban et al. [17]  
(2018)
283 Pediatric cases 
from 28 countries 
(1944–2017)
Spine was the most com-
mon site of infection.
Infants Treatment details and sus-




CKD: chronic kidney disease.
aThe outcome was unknown in 56 patients.
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tion in two of five patients. One patient had repeated isolation 
of the organism from blood cultures due to infective endocar-
ditis, and the other had nosocomial pneumonia after prolonged 
hospitalization. 
DISCUSSION
Our study identified and analyzed Elizabeth meningoseptica 
infections in patients with underlying comorbidities, particu-
larly in patients that required frequent hospitalizations. While 
many isolated case reports and series have been reported [11-
16], only a few [17] have included more than four Elizabeth-
kingia cases (Table 2). There are no reports on Elizabethkingia 
cases from Pakistan. Our study identified 16 patients in the 
last six years with Elizabethkingia meningosepticum infec-
tions. Unlike other case series with predominantly neonatal 
cases [17], our patients had a median age of 29 years. Similar 
to other case reports, the infections were urinary tract infec-
tion and meningitis [11,16]. The outcomes have been variable, 
with significant mortality among neonates [17]. However, pa-
tients with isolates susceptible to quinolones and treated with 
Ciprofloxacin had better survival outcomes [14]. This result is 
similar to patients that of who were treated with a quinolone 
in our study.
 E. meningosepticum is resistant to most commonly used 
antimicrobials; therefore, options for treatment are limited. 
Most studies have established that clinical isolates are resis-
tant to aminoglycosides and beta lactams, with notable ex-
ception of piperacillin-tazobactam, and show sensitivities to 
fluroquinolones and tetracyclines [15]. These patterns were 
consistent with the results of this study. 
 This study is a single-center case series with several inher-
ent limitations such as the small sample size and unavailabili-
ty of molecular testing and minimum inhibitory concentra-
tion data on all isolates. However, this study is the largest to 
date and the first from Pakistan, to report clinical features and 
treatment outcomes of E. meningoseptica infections. More-
over, it offers insight into the sensitivity pattern of this organ-
ism in our region. E. meningosepticum is an emerging noso-
comial pathogen that causes mortality in patients requiring 
intensive care.
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